Pascal Soriot, AstraZeneca CEO (Justin Tallis/Press Association via AP Images)

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

As As­traZeneca re­ports third-quar­ter rev­enue of al­most $11.5 bil­lion and rais­es its full-year guid­ance, the com­pa­ny is tout­ing a “favourable mix of sales” from its on­col­o­gy and rare dis­ease med­i­cines.

In a state­ment, CEO Pas­cal So­ri­ot tout­ed “strong growth tra­jec­to­ry” giv­en that the com­pa­ny booked ze­ro sales of its Covid-19 vac­cine and an­ti­bod­ies. Rev­enue growth was 5%, but when ex­clud­ing Covid-19 med­i­cines, it’s 12%. He al­so high­light­ed sev­er­al Phase III tri­al launch­es, in­clud­ing for vol­rus­tomig, a PD-1/CT­LA-4 bis­pe­cif­ic an­ti­body.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.